|3 Months Ended|
Mar. 31, 2018
|Disclosure of Compensation Related Costs, Share-based Payments [Abstract]|
NOTE 6 – STOCK OPTIONS
During the three months ended March 31, 2018, the Company granted options to purchase 1.45 million shares of common stock to the Company’s board members at exercise prices ranging from $0.14 to $0.77, vesting over a six-month period, and expiring between December 2020 and December 2022. The fair value of these options on grant date of approximately $458,000 shall be recorded as non-cash compensation expense over the vesting periods, with approximately $366,000 incurred during the three months ended March 31, 2018.
In February 2018, the former CFO of the Company exercised options to purchase 300,000 shares of common stock at an exercise price of $0.13. No options were exercised during the same period in 2017
Stock options outstanding and exercisable as of March 31, 2018 were:
The entire disclosure for compensation-related costs for equity-based compensation, which may include disclosure of policies, compensation plan details, allocation of equity compensation, incentive distributions, equity-based arrangements to obtain goods and services, deferred compensation arrangements, employee stock ownership plan details and employee stock purchase plan details.
Reference 1: http://www.xbrl.org/2003/role/presentationRef